NCT06643377View on ClinicalTrials.gov

A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 22, 2024

Primary Completion Date

June 25, 2025

Study Completion Date

June 25, 2025

Conditions
HealthyRenal Impairment
Interventions
DRUG

Enlicitide

Oral tablet

Trial Locations (5)

32132

Velocity Clinical Research, New Smyrna Beach ( Site 0003), Edgewater

32216

Jacksonville Center for Clinical Research ( Site 0004), Jacksonville

33009

Velocity Clinical Research, Hallandale Beach ( Site 0006), Hallandale

33603

Genesis Clinical Research, LLC ( Site 0001), Tampa

34452

Nature Coast Clinical Research - Inverness ( Site 0002), Inverness

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06643377 - A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032) | Biotech Hunter | Biotech Hunter